

Predictive Medicine by Cytomics

G.Valet

Max-Planck-Institut für Biochemie, Martinsried, Germany

Goal

wanted: *therapy related individualized disease course predictions*

typical: *group oriented predictions of disease prognosis like:*

- cytogenetic abnormalities and CD antigens stratify AML patients into high and low risk groups
- problem: no individualized predictions are typically obtained from group oriented data evaluation (e.g. Kaplan-Meier statistics)

Data Evaluation Strategies

predictions: individualized future

- data pattern classification (data sieving)
following exhaustive information extraction
from measured primary data

prognosis: patient group oriented future

- statistical (Kaplan-Meier, Bayes)
- cluster
- multivariate
- principal component
- fuzzy logic
- neural network



Future of Patient Groups


Kaplan-Meier Statistics
(patient stratification)



Kaplan-Meier Analysis AML

Repp et al. Cytometry 53B:11-19 (2003)

prognosis = statistical future -> patient stratification



Individualized Future

Algorithmic triple matrix
data pattern analysis
(data sieving)

Individualized Prediction by Data Pattern Classification

classification goals:

- **accuracy** for correct predictions and diagnosis
- **multiplicity** to account for the many combinatorial possibilities of genotype and exposure influences on the molecular cell phenotype

a.) *disease classification masks*
 (schematic 10 param.) disease course prediction

0000000000	stationary
+++++++++	improvement
-----	deterioration

b.) **accuracy** at low risk of random coincidence between patient and disease classification masks:

0.0017% ($1/3^{10}$) probability for random coincidence with 10 parameter masks and
0.046% ($1/3^7$) for random coincidence with 7 parameter masks

c.) *patient classification masks*
 (some examples)

0-000+00-0	stationary
00+00+0-00	stationary
-000+0-000	stationary
+++0000000	stationary
-0-00000-0	stationary
+0+-0+++00	improvement
0--0++--0	deterioration
...	...

d.) **multiplicity** of patient classification masks at correct prediction in case of partial coincidences like 7 out of 10 parameters:

$\frac{10! * 2^3}{7! * 3!} = 960$ possible patient classification masks for each disease state as potential result of genotype and exposure influences on molecular cell phenotype or other parameters



patient classification:
 highest positional coincidence with anyone of the disease classification masks

CLASSIF1 Classification


Triple Matrix Transformation of Parameter Values
using percentile thresholds of references patients

patient	numeric database columns			triple matrix database columns		
	1	2	3	1	2	3
1	40.1	4.02	18.38	0	+	0
2	39.5	4.20	5.25	-	+	-
3	41.2	3.46	35.53	0	-	+
4	53.2	3.78	30.72	+	0	+
5	41.3	3.95	27.46	0	0	0
6	79.3	3.80	16.29	+	0	0
7	48.0	3.98	28.33	0	0	0
.
.

Principle of Triple Matrix Data Pattern Classification




c. triple matrix conversion ranges
 ---- 00000000000000 ++++



- **numeric** parameter values of for example 10 **normal reference** individuals will transform on average into eight '0', one '-' and one '+' **triple matrix characters** using 10% and 90 % percentile thresholds
- similarly, parameter values of 10 **abnormal** individuals will transform at the same thresholds on average into four '0' and six **discriminatory** '+' characters according to the value distribution graph of the lower panel
- definition of a **disease classification mask** containing the characters '0' and '-' for normals and '+' for abnormal provides the **correct classification** of 90% **normals** as normals and of 60% **abnormals** as abnormal
- **disease classification masks** with typically between 5 and 25 classification parameters increase the **discrimination potential** and allow accurate diagnosis and predictions on therapy dependent future disease course in individual patients from patient classification masks with **accuracies >95% or >99%**

Information Enrichment by Data Sieving

discri-
mination:



CLASSIF1 algorithm:

- sequential data partitioning into 50 parameter (data columns) wide data sieves
- select 5 most discriminatory parameters in each sieve by **percentile analysis**
- combine selected parameters, repartition, sieve & repeat procedure until 50 columns or less remain
- classify remaining data columns for **most discriminatory triple matrix** data pattern
- algorithm characteristics: **surface data mining** (no models), **unsupervised exhaustive knowledge extraction** to access **unknown knowledge spaces**

GVAL

Classification Matrix

goal: optimize diagonal sum

clinical outcome	CLASSIF1 prediction (%)		
	stationary	improve	deteriorate
stationary	100.0	0.0	0.0
improve	0.0	100.0	0.0
deteriorate	0.0	0.0	100.0
neg/pos predval	100.0	100.0	100.0

procedure:

- classify all parameters
- cross validate: sequential temporary removal of single parameters
- reclassification
- retain increase or decrease of diagonal sum
- reinsert parameter
- finally: remove parameters decreasing diagonal sum

Individualized Pretherapeutic Identification of High Risk Acute Myeloid Leukemia (AML) Patients

Valet G.1), Repp R.2), Link H.3), Ehninger G.4), Gramatzki M.2)
and SHG-AML'96 Group

1) Max-Planck-Institut für Biochemie, Martinsried, 2) Med.Klinik III Univ. Erlangen, 3) Klinikum Kaiserslautern, 4) Med.Klinik & Poliklinik I Univ.Dresden

Cytometry (2003) 53B:4-10

SHG-96 Multicenter AML Trial: Parameters

clinical parameters	cytogenetics		CD-antigens		
pat_age	cytogen	t1_7	CD1	CD34	GlyA
pat_sex		abnorm	t3_3	CD2	MPO7
zz_mio	del5	t6_9	CD4	CD38	TH126
leuk	del7	t9_11	CD7	CD41	TC12
LDH	dely	t9_22	CD9	CD42	TC25
flt3	mono	t15_17	CD10	CD45	TDT
clinic_nr	inv3	abn12	CD11b	CD56	cyCD3
patient_nr	tri8	abn11	CD14	CD58	HLA-DR
OS	tri11	aberr_m	CD15	CD61	(n=36)
(n=6)	tri13	inv16	CD19	CD64	
	tri21	other_ab	CD20	CD75	
	tri22		CD24	CD95	
	t8_21	(n=25)	CD32	CD96	
	t8_16		CD33	CD117	

= survival indicator

classification parameters: n=67

= not used for > 5year survival (less than 10% available values)

val

Pretherapeutic Identification of High Risk AML Patients

learning set

clinical outcome	pat. (n)	CLASSIF1 prediction (%)	
		>5y surv	non surv
>5y surv	24	100.0	0.0
non surv	269	50.2	49.8
neg/pos predval		15.1	100.0

unknown embedded test set

non surv	165	8.5	91.5
----------	-----	-----	------

20-75% percentiles, DJ/REPP32.BI4

AML: Predictive Parameters

5 year survival

#	parameter	S	NS
1	zz_mio	-0	+
2	pat.age	-0	+
3	% CD2	-0	+
4	% CD4	-0	+
5	% CD13	-0	+
6	% CD36	-0	+
7	% CD45	-0	+

selected parameters: 7/67 → 10.5%

Conclusions

Predictive Medicine by Cytomics

- data pattern classification identifies a significant proportion of high risk patients individually prior to therapy as shown for AML patients as an example
- this is an important prerequisite for individualized/personalized therapy in stratified (Kaplan-Meier) patient groups
- detailed knowledge on the mechanisms of disease induction is not required for this approach

VAL

Data Pattern Classification

for further details see:

<https://www.classimed.de/classif1.html>

<https://www.classimed.de/cellclas.html>